By Michael Dabaie
RedHill Biopharma Ltd. said an analysis showed its oral opaganib reduces mortality by 70% given on top of remdesivir and corticosteroids in severe Covid-19.
The company said its prespecified analysis of Phase 2/3 opaganib data in severe Covid-19 patients showed a significant, 70.2% mortality benefit with opaganib by day 42 when given on top of the best available standard-of-care, remdesivir and corticosteroids.
A second analysis showed that opaganib also delivered a significant 34% benefit in time to recovery by day 14, with 37.4% of opaganib-treated patients reaching this event versus 27.9% of patients treated with placebo plus standard of care.
RedHill said it is advancing regulatory discussions in multiple countries, with potential emergency and marketing authorization applications being planned for certain countries in the first half of 2022.
Write to Michael Dabaie at [email protected]